Platform for myocardial infarct MRI and delivery of therapeutics

Award Information
Agency: Department of Health and Human Services
Branch: N/A
Contract: 1R41HL116014-01
Agency Tracking Number: R41HL116014
Amount: $379,160.00
Phase: Phase I
Program: STTR
Awards Year: 2012
Solitcitation Year: 2012
Solitcitation Topic Code: NHLBI
Solitcitation Number: PA11-097
Small Business Information
CELSENSE, INC.
603 STANWIX STREET, SUITE 348, PITTSBURGH, PA, 15222-
Duns: 798793548
Hubzone Owned: N
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
 ERIC AHRENS
 (412) 268-5105
 eta@celsense.com
Business Contact
 AMY WESA
Phone: (412) 263-2870
Email: awesa@celsense.com
Research Institution
 CELSENSE, INC.
 603 STANWIX STREET
SUITE 348
PITTSBURGH, PA, 15222-
 () -
 Domestic nonprofit research organization
Abstract
Myocardial infarction (MI) afflicts more than one million persons per year in the United States alone. MI results in permanent left ventricle (LV) scarring that causes diminished pump efficiency and, commonly, heart failure. Towards reduction or elimination of scarring, there is increasing interest in reparative biological materials, such as cells and proteins, that are introduced into the affected region of the LV early after MI. We believe that such an approach will eventually become part of a standard ofcare. The most promising route for the delivery of such materials is direct LV injection (DLVI). Thus far, the utility of DLVI has been hampered by the lack methods for accurate spatial targeting of affected tissue. This has greatly impeded clinical translation of promising materials. The goal of this project is to devise cutting edge imaging tools to visualize infarcted regions using MRI.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government